News from our Partners
Find out the latest from our Partners and Affiliates
Dr. Kristen Krysko Wins 2025 Rachel Horne Prize For Women’s Research In Multiple Sclerosis
Dr Kristen Krysko, a Canadian neurologist, researcher and clinician, is the winner of the Rachel Horne Prize for Women’s Research in [...]
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
Is it MS or Something Else? updated guide is published to expedite and uncover the answer
MIDDLETON, WI., July 19, 2023 - An international consortium led by the Americas Committee for Treatment and Research in Multiple [...]
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
Phase III OCARINA II trial met primary and secondary endpoints Ocrevus 10-minute injection has the potential to further improve the [...]
NeurologyLive® and CMSC announce Giants of Multiple Sclerosis® 2023 class of inductees
CRANBURY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased [...]
Multiple sclerosis discovery could end disease’s chronic inflammation
CHARLOTTESVILLE – Multiple sclerosis affects nearly a million Americans. Symptoms can include muscle spasms, stiffness, weakness, [...]
Congratulations to Dr. Carrie Hersh for her recent publication on DMTs
Updates and advances multiple sclerosis neurotherapuetics Moein Amin1 & Carrie M Hersh*,2 1Cleveland Clinic, Department of [...]
The launch of the ROADMAP tool on Rare Disease Day 2023
The Castleman Disease Collaborative Network (CDCN) is delighted to announce the launch of the ROADMAP drug repurposing tool. The [...]
Meghan Beier recently joined the Rowan Center for Behavioral Health
Meghan Beier recently joined the Rowan Center for Behavioral Health. Rowan is a well-established psychotherapy practice focused on [...]
Helius launches UpScript telehealth e-commerce site
PDF Version New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 [...]
A new patient assistance offering from Janssen
FOR INSURED PATIENTS WHO ARE FACING ACCESS AND AFFORDABILITY CHALLENGES Janssen believes that access and affordability challenges [...]
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Janssen Pharmaceuticals U.S. transparency report
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Genentech premiers #MSVisibility 2022
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Sanofi’s 2022 annual pricing principles report
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
MR epectroscopic imaging may help better diagnose, treat multiple sclerosis
Magnetic resonance spectroscopic imaging (MRSI) performed at 7.0 T (7.0-T MRSI) could visualize pathologic findings of multiple sclerosis [...]
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
NeurologyLive® announces the inaugural Giants of Multiple Sclerosis™ Program
NeurologyLive® Announces the Inaugural Giants of Multiple Sclerosis™ Program The first annual award program will honor [...]
The Brain Under Siege by Dr. Howard Weiner
The CMSC and IOMSN are proud to announce the following: Dr. Howard L. Weiner has just written a new book on brain diseases called The [...]
Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ET on an [...]
MRI in Multiple Sclerosis Guidelines Update: North America, Europe align on new recommendations
These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more [...]
Congratulations to Dr. Robert Lisak: recipient of ANA’s Distinguished Neurology Teacher Award
The CMSC Board, staff, and members would like to congratulate Dr. Robert Lisak for his selection as a recipient of the 2021 Distinguished [...]
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
NeurologyLive® & the CMSC launches MS Cure Connections® Video Series
A diverse panel including an expert neurologist, a psychologist, a patient, and a care partner discuss the patient's journey with [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
WHO and AMA statement
"The Trump administration's official withdrawal from the World Health Organization (WHO) puts the health of our country at grave risk. As [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Multiple sclerosis patients can benefit from expanded services from MSAA
In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has [...]
ZEPOSIA launch press release
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]
New 6-year data for Genentech’s Ocrevus (ocrelizumab) findings
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in [...]
Coronavirus and multiple sclerosis reporting database
COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the Consortium of MS Centers (CMSC) and the National MS [...]
FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis
The U.S. Food and Drug Administration (FDA) has approved Zeposia (ozanimod) oral capsules to treat adults with relapsing forms [...]
CMSC update on COVID-19: NMSS National Medical Advisory Committee recommendations
The Centers for Disease Control and Prevention (CDC) are following the outbreak of coronavirus (COVID-19), which causes a respiratory [...]
Multiple sclerosis and COVID-19 registry
Dear Colleagues and Clients: We know you are interested in what happens to people with MS and related diseases who develop [...]
Please read: Coronavirus and multiple sclerosis statement
The MS International Federation (also known as MSIF) has compiled information and a video (available here) which sufficiently [...]
Brain activity patterns linked with improved learning and memory in multiple sclerosis
A recent article by Kessler Foundation researchers demonstrated g people with multiple sclerosis (MS). The article, "Brain activation [...]
Robotic ‘trousers’ could help thousands of multiple sclerosis sufferers stand and walk again
Robotic ‘trousers’ could help thousands of people left unable to stand or walk due to multiple sclerosis find their feet again. The [...]
